Bosutinib

Overview

Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC 50 of 1.2 nM and 1 nM, respectively.

Application

Products | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Src | Products > Signaling Pathways > Bcr-Abl | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-10158
• CAS No.: 380843-75-4
• Molecular Formula: C26H29Cl2N5O3
• Molecular Weight: 530.45
• Purity: 99.97%
• Storage: 4°C, protect from light * In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
• Solubility: ≥ 2.5 mg/mL (4.71 mM); Clear solution
• Availability: In-stock

Source

Original product source